Download MendeleyThe Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor.
Goldberg, F.W., Finlay, M.R.V., Ting, A.K.T., Beattie, D., Lamont, G.M., Fallan, C., Wrigley, G.L., Schimpl, M., Howard, M.R., Williamson, B., Vazquez-Chantada, M., Barratt, D.G., Davies, B.R., Cadogan, E.B., Ramos-Montoya, A., Dean, E.(2020) J Med Chem 63: 3461-3471
- PubMed: 31851518
- DOI: https://doi.org/10.1021/acs.jmedchem.9b01684
- Primary Citation of Related Structures:
6T2W, 6T3B, 6T3C - PubMed Abstract:
DNA-PK is a key component within the DNA damage response, as it is responsible for recognizing and repairing double-strand DNA breaks (DSBs) via non-homologous end joining. Historically it has been challenging to identify inhibitors of the DNA-PK catalytic subunit (DNA-PKcs) with good selectivity versus the structurally related PI3 (lipid) and PI3K-related protein kinases. We screened our corporate collection for DNA-PKcs inhibitors with good PI3 kinase selectivity, identifying compound 1 . Optimization focused on further improving selectivity while improving physical and pharmacokinetic properties, notably co-optimization of permeability and metabolic stability, to identify compound 16 (AZD7648). Compound 16 had no significant off-target activity in the protein kinome and only weak activity versus PI3Kα/γ lipid kinases. Monotherapy activity in murine xenograft models was observed, and regressions were observed when combined with inducers of DSBs (doxorubicin or irradiation) or PARP inhibition (olaparib). These data support progression into clinical studies (NCT03907969).
Organizational Affiliation:
Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K.
